Ayala Pharmaceuticals Inc (ADXS)

[gold007_2000]

Remember the deal Aduro made with Novartis $200 million up front

I'm wondering what Novartis is thinking after Amgen terminated with Advaxis

Under the agreement, Novartis is paying $200 million up front to kick off a collaboration on small-molecule therapies that target a pathway called STING, or stimulator of interferon genes. Aduro's preclinical candidates are cyclic dinucleotides--chemicals naturally expressed by bacteria and immune cells--that stimulate a STING response and thereby help the body's natural defenses better recognize and attack tumors, the company said.